04937nam 2201333z- 450 991055766640332120231214133700.0(CKB)5400000000044842(oapen)https://directory.doabooks.org/handle/20.500.12854/76871(EXLCZ)99540000000004484220202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierDrug-Drug InteractionsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (242 p.)3-0365-2035-X 3-0365-2036-8 Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.Research & information: generalbicsscBiology, life sciencesbicssctadalafilticagrelordrug-drug interactionpharmacokineticsplasma concentrationCYP3A4LoxoprofenCYP3ADexamethasoneKetoconazoleCYP2D6O-desmethyltramadolphysiologically-based pharmacokineticstramadol(‒)-sophoranoneCYP2C9potent inhibitionin vitroin vivodrug interactionlow permeabilityhigh plasma protein bindingbiflavonoidcytochrome P450drug interactionsselamariscina Auridine 5′-diphosphoglucuronosyl transferasetissue-specificsystemic exposureP-glycoprotein (P-gp)organic anion transporting polypeptide 1A2 (OATP1A2)Rumex acetosafexofenadinechronic kidney diseasedrug–drug interactionspolypharmacyadverse drug reactionsLexicompsubset analysissignal detection algorithmsspontaneous reporting systemsmechanism-based inhibitioncompetitive inhibitionnon-competitive inhibitionsubstrateinhibitorcytochromes P450OATP1B1OATP1B3tyrosine kinase inhibitorsdrug-drug interactionsmigrainelasmiditangepantsmonoclonal antibodiesCYP1A1CYP1A2drug–drug interactionexpressionmetabolismregulationdrug transporterubiquitinationixazomibDDIcomputational predictionin silicoQSARdrug metabolismADMECYPmetabolic DDIP4501A22B62C192C82C92D63A4Research & information: generalBiology, life sciencesKim Dong Hyunedt1304704Lee SangkyuedtKim Dong HyunothLee SangkyuothBOOK9910557666403321Drug-Drug Interactions3027633UNINA